WO2008048801A3 - Phenylalkylamino carbamate compositions - Google Patents

Phenylalkylamino carbamate compositions Download PDF

Info

Publication number
WO2008048801A3
WO2008048801A3 PCT/US2007/080675 US2007080675W WO2008048801A3 WO 2008048801 A3 WO2008048801 A3 WO 2008048801A3 US 2007080675 W US2007080675 W US 2007080675W WO 2008048801 A3 WO2008048801 A3 WO 2008048801A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenylalkylamino carbamate
phenylalkylamino
carbamate compositions
carbamate compound
compositions
Prior art date
Application number
PCT/US2007/080675
Other languages
French (fr)
Other versions
WO2008048801A2 (en
Inventor
Ramendra N Pandey
Tracey Mascaro
Aniruddha M Railkar
James Mccool
Hinton Clark
Stanley Altan
Original Assignee
Janssen Pharmaceutica Nv
Ramendra N Pandey
Tracey Mascaro
Aniruddha M Railkar
James Mccool
Hinton Clark
Stanley Altan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Ramendra N Pandey, Tracey Mascaro, Aniruddha M Railkar, James Mccool, Hinton Clark, Stanley Altan filed Critical Janssen Pharmaceutica Nv
Priority to AU2007313017A priority Critical patent/AU2007313017A1/en
Priority to MX2009003926A priority patent/MX2009003926A/en
Priority to EA200970377A priority patent/EA200970377A1/en
Priority to EP07843957A priority patent/EP2079449A2/en
Priority to CA002673487A priority patent/CA2673487A1/en
Priority to BRPI0719275-4A2A priority patent/BRPI0719275A2/en
Priority to JP2009532514A priority patent/JP2010506845A/en
Publication of WO2008048801A2 publication Critical patent/WO2008048801A2/en
Publication of WO2008048801A3 publication Critical patent/WO2008048801A3/en
Priority to IL198145A priority patent/IL198145A0/en
Priority to NO20091530A priority patent/NO20091530L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a composition of a phenylalkylamino carbamate compound that results in improved stability, wherein the composition comprises a phenylalkylamino carbamate compound in a mixture with an effective amount of one or more excipients wherein at least one excipient is dibasic calcium phosphate dihydrate.
PCT/US2007/080675 2006-10-13 2007-10-08 Phenylalkylamino carbamate compositions WO2008048801A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2007313017A AU2007313017A1 (en) 2006-10-13 2007-10-08 Phenylalkylamino carbamate compositions
MX2009003926A MX2009003926A (en) 2006-10-13 2007-10-08 Phenylalkylamino carbamate compositions.
EA200970377A EA200970377A1 (en) 2006-10-13 2007-10-08 COMPOSITIONS OF PHENYLCALAMINOCARBAMATE
EP07843957A EP2079449A2 (en) 2006-10-13 2007-10-08 Phenylalkylamino carbamate compositions
CA002673487A CA2673487A1 (en) 2006-10-13 2007-10-08 Phenylalkylamino carbamate compositions
BRPI0719275-4A2A BRPI0719275A2 (en) 2006-10-13 2007-10-08 PHENYL-ALKYL-AMINO CARBAMATE COMPOSITIONS
JP2009532514A JP2010506845A (en) 2006-10-13 2007-10-08 Phenylalkylaminocarbamate composition
IL198145A IL198145A0 (en) 2006-10-13 2009-04-16 Phenylalkylamino carbamate compositions
NO20091530A NO20091530L (en) 2006-10-13 2009-04-17 Phenylalkylaminocarbamate preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82934206P 2006-10-13 2006-10-13
US60/829,342 2006-10-13

Publications (2)

Publication Number Publication Date
WO2008048801A2 WO2008048801A2 (en) 2008-04-24
WO2008048801A3 true WO2008048801A3 (en) 2008-06-05

Family

ID=39111348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080675 WO2008048801A2 (en) 2006-10-13 2007-10-08 Phenylalkylamino carbamate compositions

Country Status (19)

Country Link
US (1) US20080090902A1 (en)
EP (1) EP2079449A2 (en)
JP (1) JP2010506845A (en)
KR (1) KR20090082213A (en)
CN (1) CN101557804A (en)
AU (1) AU2007313017A1 (en)
BR (1) BRPI0719275A2 (en)
CA (1) CA2673487A1 (en)
CO (1) CO6180500A2 (en)
CR (1) CR10794A (en)
EA (1) EA200970377A1 (en)
GT (1) GT200900082A (en)
IL (1) IL198145A0 (en)
MX (1) MX2009003926A (en)
NI (1) NI200900053A (en)
NO (1) NO20091530L (en)
SV (1) SV2009003221A (en)
WO (1) WO2008048801A2 (en)
ZA (1) ZA200903283B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613697A2 (en) 2005-06-08 2011-01-25 Sk Holdings Co Ltd sleep-wake disorders treatment
CN106727486A (en) 2009-06-22 2017-05-31 爱思开生物制药株式会社 Treatment or the method for prevention fatigue
CN102762201B (en) 2009-11-06 2013-12-18 爱思开生物制药株式会社 Methods for treating attention-deficit/hyperactivity disorder
MX350745B (en) * 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * Methods for treating fibromyalgia syndrome.
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
KR101717872B1 (en) 2013-03-12 2017-03-17 (주)바이오팜솔루션즈 Phenyl carbamate compounds for use in preventing or treating pediatric epilesy and epilesy-related syndromes
CN105209430B (en) 2013-03-12 2019-09-13 比皮艾思药物研发有限公司 Carbanilate compound and neuroprotective composition comprising it
DK2968208T3 (en) 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd TREATMENT OF CATAPLEXIA
KR102309836B1 (en) 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 Treatment for obesity
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CA3065522A1 (en) 2017-06-02 2018-12-06 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
CN110037995B (en) * 2019-04-17 2021-07-06 石家庄龙泽制药股份有限公司 Stable paroxetine hydrochloride tablet and preparation method thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
IT202000013855A1 (en) 2020-06-10 2021-12-10 Flamma Spa A PROCESS FOR THE PURIFICATION OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007637A1 (en) * 1994-09-09 1996-03-14 Yukong Limited Novel phenylalkylaminoalcohol carbamates and process for preparing the same
WO1998015526A1 (en) * 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342687A (en) * 1964-06-25 1967-09-19 Colgate Palmolive Co Oral preparation
US3420817A (en) * 1966-12-06 1969-01-07 Hoffmann La Roche 4,1,5-benzoxadiazocin-2-ons and processes for preparing same
US6372438B1 (en) * 1988-02-02 2002-04-16 The Regents Of The University Of California Human platelet-derived growth factor receptors
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (en) * 1995-02-11 1999-04-01 조규향 O-carbamoyl- (D) -phenylalaninol compounds and their pharmaceutically useful salts and methods for their preparation
KR0173863B1 (en) * 1995-04-10 1999-04-01 조규향 O-carbamoyl-phenylalanineol compounds having substituents on phenyl, pharmaceutically useful salts thereof, and preparation methods thereof
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
IL154422A0 (en) * 2000-08-28 2003-09-17 Synthon Bv Paroxetine compositions and processes for making the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007637A1 (en) * 1994-09-09 1996-03-14 Yukong Limited Novel phenylalkylaminoalcohol carbamates and process for preparing the same
WO1998015526A1 (en) * 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LANDIN M ET AL: "Chemical stability of acetylsalicylic acid in tablets prepared with different commercial brands of dicalcium phosphate dihydrate", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 107, no. 3, 1994, pages 247 - 249, XP002471444, ISSN: 0378-5173 *
LANDIN M ET AL: "Chemical stability of acetylsalicylic acid in tablets prepared with different particle size fractions of a commercial brand of dicalcium phosphate dihydrate", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 123, no. 1, 1995, pages 143 - 144, XP002471443, ISSN: 0378-5173 *

Also Published As

Publication number Publication date
WO2008048801A2 (en) 2008-04-24
ZA200903283B (en) 2010-07-28
JP2010506845A (en) 2010-03-04
NO20091530L (en) 2009-07-06
AU2007313017A1 (en) 2008-04-24
CO6180500A2 (en) 2010-07-19
KR20090082213A (en) 2009-07-29
IL198145A0 (en) 2009-12-24
MX2009003926A (en) 2009-06-26
EP2079449A2 (en) 2009-07-22
CN101557804A (en) 2009-10-14
BRPI0719275A2 (en) 2014-04-29
CR10794A (en) 2009-09-29
NI200900053A (en) 2010-02-01
SV2009003221A (en) 2010-04-15
CA2673487A1 (en) 2008-04-24
US20080090902A1 (en) 2008-04-17
EA200970377A1 (en) 2009-10-30
GT200900082A (en) 2010-02-24

Similar Documents

Publication Publication Date Title
WO2008048801A3 (en) Phenylalkylamino carbamate compositions
MX2009003929A (en) Phenylalkyl carbamate compositions.
WO2006031922A3 (en) Thyroid hormone analogs for promoting angiogenesis
WO2008112939A3 (en) Composition and method for making oligo-benzamide compounds
EP2086540B8 (en) Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
WO2006074951A3 (en) Orally disintegrating composition of olanzapine or donepezil
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
BRPI0514766A (en) pharmaceutical compositions
EP2647692A3 (en) Compositions and methods comprising serine protease variants
WO2008079291A3 (en) Substituted heterocycles and methods of use
WO2008013840A3 (en) Erastin analogs and uses thereof
WO2007031933A3 (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2009147205A3 (en) Synergistic fungicidal mixtures
WO2005086836A3 (en) Ion channel modulators
WO2009009041A3 (en) Compositions and methods for modulating a kinase cascade
TNSN07222A1 (en) Nematicidal compositions
WO2006013475A3 (en) Photoresist compositions
WO2005086895A3 (en) Ion channel modulators
WO2005086902A3 (en) Ion channel modulators
MX2013004162A (en) Pharmaceutical compositions containing a dgat1 inhibitor.
WO2005075467A3 (en) Crystalline forms of zolmitriptan
WO2005097112A3 (en) Ion channel modulators
WO2007057748A3 (en) Use of colostrum for the prophylaxis of influenza syndromes
WO2007096703A3 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
TN2009000244A1 (en) Formulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780045800.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843957

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009040484

Country of ref document: EG

Ref document number: 2007313017

Country of ref document: AU

Ref document number: 2673487

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009532514

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12009500686

Country of ref document: PH

Ref document number: MX/A/2009/003926

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 576210

Country of ref document: NZ

Ref document number: 09037414

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 198145

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020097009750

Country of ref document: KR

Ref document number: 200970377

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: a200904711

Country of ref document: UA

Ref document number: 2007843957

Country of ref document: EP

Ref document number: CR2009-010794

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2007313017

Country of ref document: AU

Date of ref document: 20071008

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0719275

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090409